NASDAQ: TRVI Trevi Therapeutics, Inc. 8-K

Trevi Therapeutics prices $141M equity offering to fund Phase 3 chronic cough trials through 2029

Filed April 17, 2026 · Period ending April 16, 2026 · ~1 min read

5 material changes detected in this filing.

Create a free account to read the full summary — it takes 30 seconds.

Partner

Trade TRVI commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Generated by AI · Jun 5, 2026 5:10 PM